Abstracts tagged "systematic review"

Abstract Number: 0842 • ACR Convergence 2021
What Is the Success Rate in Clinical Trials of Discontinuation Glucocorticoids After Their Use as Bridging Therapy – a Systematic Literature Review
Lotte van Ouwerkerk¹, Isabell Nevins¹, Patrick Verschueren², Josef Smolen³, Robert Landewé⁴, Johannes Bijlsma⁵, Andreas Kerschbaumer³, Tom WJ Huizinga¹, Rene Westhovens⁶, Cornelia F. Allaart¹ and Sytske Anne Bergstra¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospitals Leuven - KULeuven, Leuven, Belgium, ³Medical University of Vienna, Vienna, Austria, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶University Hospitals KU Leuven, Maaseik, Belgium
Background/Purpose: Short-term glucocorticoid (GC) bridging therapy results in rapid suppression of disease activity during the initial treatment of rheumatoid arthritis (RA) patients with DMARDs. But…
Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Esteban Rubio¹, Alejandro Muñoz ¹ and Núria Casamira ², ¹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ²Medical Department, Gebro Pharma S.A., Barcelona, Spain
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
Abstract Number: 1304 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis
Xavier Chevalier ¹, Brendan Sheehan ², Craig Whittington ³, Chunyi Ho ⁴, Wilson Ngai⁵ and Gustavo Campos ⁶, ¹Department of Rheumatology, Hospital henri Mondor, Paris University XII, Creteil, France, ²Department of Medicine, Dalhousie University, Saint John, NB, Canada, ³Doctor Evidence, Santa Monica, CA, ⁴Doctor Evidence, Santa Monica, ⁵Sanofi, U.S. Medical Affairs, Bridgewater, ⁶Universidade Estadual de Campinas, Campinas, Brazil
Background/Purpose: Knee OA is a progressive joint disease which affects more than 250 million people worldwide. Meta-analysis (MA) has demonstrated that IA CS were more…
Abstract Number: 2367 • 2019 ACR/ARP Annual Meeting
The Effect of DMARDs on Cardiovascular Outcomes in Rheumatoid Arthritis: A Systematic Literature Review
Vardhaman Patel¹, Leticia Ferri ², Xue Han ², Lauren Mintzer ³ and Mir Sohail Fazeli ³, ¹Bristol-Myers Squibb, New York City, NY, ²Bristol-Myers Squibb Company, Princeton, NJ, ³Doctor Evidence, Santa Monica, CA
Background/Purpose: Autoantibodies and chronic systemic inflammation experienced in rheumatoid arthritis (RA) increases the risk of cardiovascular disease (CVD). This systematic literature review (SLR) aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].